Join Aligos Therapeutics (#ALGS) for a virtual KOL event on Thurs. July 18 at 3pm ET featuring Mark Sulkowski, MD (Johns Hopkins University School of Medicine), who will join company management to review positive Phase 1b data from the ongoing ALG-000184 clinical study presented at #EASL2024. Register: https://bit.ly/3WrdZ5D
LifeSci Advisors, LLC
Financial Services
New York, New York 14,717 followers
Accelerating Innovations In Life Science.
About us
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences field with a comprehensive solution to investor communications and outreach. Our services are designed to increase our clients’ visibility within the investment community and to educate investors about the opportunity. We strive to effectively communicate each clients’ unique value proposition, building momentum for the investment. We begin with deep due diligence as we partner with each client to gain an unparalleled level of understanding of their business and the opportunities they are addressing. This in-depth knowledge allows us to be able to provide each client partner with thoughtful recommendations related to corporate communications, investor outreach, and capital markets planning. Our strategies and actions are specifically tailored to help each client achieve their investor relations goals.
- Website
-
http://www.lifesciadvisors.com
External link for LifeSci Advisors, LLC
- Industry
- Financial Services
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Investor Relations
Locations
-
Primary
250 W 55th St
#3401
New York, New York 10019, US
Employees at LifeSci Advisors, LLC
Updates
-
Join Biora Therapeutics (#BIOR) for a virtual KOL event on Weds. July 17 at 2pm ET featuring Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai) and Brian Feagan, MD, FRCPC (Schulich School of Medicine & Dentistry at the University of Western Ontario), who will discuss the unmet need and current treatment landscape for patients with ulcerative colitis (UC), as well as the value of colonic drug delivery for improving efficacy. Register here: https://bit.ly/3S0bWCG
-
-
Join Purple Biotech (#PPBT) for a virtual KOL event on Thurs. July 11 at 10:30am ET featuring Michael Cecchini, MD (Yale School of Medicine) and E. Gabriela Chiorean, MD (Fred Hutchinson Cancer Center, University of Washington School of Medicine), who will discuss the positive interim data from the Phase 2 study of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (#PDAC). Register here: https://bit.ly/3Wgzo14
-
-
Join Arrowhead Pharmaceuticals (#ARWR) for Part III of its Summer Series of R&D webinars on Tues. July 16 at 2pm ET featuring Matthias A. Salathe, MD (University of Kansas Medical Center) to provide updates on its key pulmonary programs in Phase 1/2 development: ARO-RAGE, ARO-MMP7, and ARO-MUC5AC. Register here: https://bit.ly/3Wg2Zb5
-
-
Join FibroGen, Inc. (#FGEN) for Part II of a virtual KOL investor event series on Wed. June 26 at 10am et featuring Rahul Aggarwal, MD (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246, a CD46 targeting antibody-drug conjugate (ADC) with first-in-class potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Register here: https://bit.ly/45zUaMl
-
-
Join us this Wednesday, June 26 at 1pm ET for the latest in our "Lunch with LifeSci" series, where we will interview Todd Davis, CEO of Ligand Pharmaceuticals (#LGND) to get an inside look at the biopharmaceutical royalty aggregator and its impressive portfolio. Register now: https://bit.ly/3xw9Ao2
-
-
Join Brainomix for a virtual KOL event on Mon. June 24 at 10am ET featuring Dr. Waleed Brinjikji, M.D. (Mayo Clinic), who will join company leadership to provide a detailed look at the Brainomix 360 Stroke platform, an FDA-cleared and CE-marked collection of tools that use state-of-the-art AI algorithms to provide real-time interpretation of brain scans across the full stroke pathway. Register here: https://lnkd.in/eqaK3PBD
-
-
Join Arrowhead Pharmaceuticals (#ARWR) for Part II of its summer series of R&D webinars on Tues. June 25 at 2pm ET featuring Christie M. Ballantyne, MD, FACP, FACC (Baylor College of Medicine), including updates on two of its key cardiometabolic programs: plozasiran and zodasiran. Register here: https://bit.ly/4bZMdSP
-
-
Don't miss it! R1 RCM is hosting a virtual investor event on Thurs. June 27 at 11 am ET featuring Steven Albert and Brian Gambs. Register here: https://lnkd.in/gmJaY_CA
Join R1 RCM for a virtual investor event on Thurs. June 27 at 11 am ET featuring Steven Albert, Executive Vice President and Chief Product Officer, and Brian Gambs, Executive Vice President and Chief Technology Officer, who will provide an overview of the R1 Platform and key areas of innovation. The event will highlight key advantages of the platform, new AI innovation, and select focus areas of R1’s future technology roadmap. Register here: https://lnkd.in/gmJaY_CA #RCM #Technology #RevenueCycle
-
-
Join X4 Pharmaceuticals for a virtual investor day on Thurs. June 27 at 8am ET, featuring Peter E. Newburger, MD (UMass Chan Medical School) and Jean Donadieu, MD, PhD (Trousseau Hospital, Paris). Register here: https://lnkd.in/eVPTy9Mb
Don't forget to register for our June 27th virtual investor event where we will review new clinical data on our lead product candidate from our ongoing Phase 2 trial in #ChronicNeutropenia. We are excited to include renowned experts Dr. Jean Donadieu, MD, PhD, and Dr. Peter E. Newburger, MD, who will share their insights on the interim results and the high unmet need in CN. Register now by clicking the link here: https://bit.ly/3VuyTQu #Progress4Patients
-